Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
      Description

      This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

      Conditions
      Carcinoid TumorFunctioning Pancreatic Neuroendocrine TumorIntermediate Grade Lung Neuroendocrine NeoplasmLocally Advanced Digestive System Neuroendocrine NeoplasmLocally Advanced Digestive System Neuroendocrine Tumor G1Locally Advanced Lung Neuroendocrine NeoplasmLocally Advanced Pancreatic Neuroendocrine TumorLocally Advanced Unresectable Digestive System Neuroendocrine NeoplasmLow Grade Lung Neuroendocrine NeoplasmLung Neuroendocrine TumorLung Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Digestive System Neuroendocrine Tumor G1Metastatic Lung Neuroendocrine NeoplasmMetastatic Lung Neuroendocrine TumorMetastatic Pancreatic Neuroendocrine NeoplasmMetastatic Pancreatic Neuroendocrine TumorMetastatic Thymus Neuroendocrine NeoplasmNeuroendocrine NeoplasmNeuroendocrine Tumor G2Non-Functioning Pancreatic Neuroendocrine TumorPancreatic Serotonin-Producing Neuroendocrine TumorThymus Neuroendocrine TumorUnresectable Digestive System Neuroendocrine NeoplasmUnresectable Digestive System Neuroendocrine Tumor G1Unresectable Lung Neuroendocrine NeoplasmUnresectable Pancreatic Neuroendocrine NeoplasmUnresectable Thymus Neuroendocrine Neoplasm
      Talk to us
      WITHDRAWN
      Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
      Description

      Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET. The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.

      Conditions
      Pulmonary Neuroendocrine NeoplasmPheochromocytomaParagangliomaThymus CarcinoidUnknown Primary TumorsNeuroendocrine TumorsNeuroendocrine Skin CarcinomaNeuroendocrine Breast TumorNeuroendocrine Carcinoma MetastaticNeuroendocrine Neoplasm of Ovary
      Talk to us